Trials for patients who have had previous drug treatment

A Study of 23ME-00610 in Patients with Advanced Kidney Cancer

Background: 23ME-00610 belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Some notable approved immune checkpoint inhibitors for kidney cancer include Nivolumab (Opdivo®), Ipilimumab (Yervoy®),...

Kidney Cancer Canada